Claret Bioscience LLC, builds tools for improved precision oncology by developing novel next-generation sequencing (NGS) approaches for a deeper understanding of cell-free DNA fragmentomics . Their unique library preparation technologies SRSLY and XACTLY capture and encode native DNA termini information and other features of cfDNA fragmentation that are lost in traditional NGS methods. ClaretBio’s mission is to enhance the quality of DNA sequencing data obtained from highly degraded, low yield samples and provide tools for accurate disease profiling using DNA fragmentomics.